It's about recognizing the full scope of the condition
For the roughly 170 million women and adolescents living with polycystic ovary syndrome, a name has long told an incomplete story — pointing to the ovaries while a far larger disruption unfolds across the body's metabolic, endocrine, and psychological systems. Researchers publishing in The Lancet now propose renaming the condition polyendocrine metabolic ovarian syndrome, or PMOS, arguing that language shapes diagnosis, care, and ultimately lives. The proposal reflects a quiet truth medicine has been slow to honor: that what we call a disease determines, in no small part, how seriously we take it.
- One in eight women worldwide carries a diagnosis whose name actively misleads — pointing to the ovaries while insulin resistance, cardiovascular risk, and depression quietly accumulate in the background.
- Patients are falling through the cracks of a siloed medical system, bouncing between gynecologists and endocrinologists while no single specialist sees the full picture the current name obscures.
- Teenagers face a particularly disorienting contradiction: told they have an ovarian disease, then watched as doctors set aside the ovaries entirely to focus on blood sugar and hormone markers.
- Researchers are pushing for the name PMOS — polyendocrine metabolic ovarian syndrome — to force the medical establishment to treat the condition as the whole-body disease it actually is.
- A renamed condition could unlock multidisciplinary care teams, reduce diagnostic delays, lift the stigma of a 'fertility problem,' and attract the research funding currently reserved for diabetes and heart disease.
A condition affecting roughly 170 million women and adolescents worldwide may soon carry a new name — one researchers say finally tells the truth about what it does to the body.
For decades, polycystic ovary syndrome, or PCOS, has been treated as a reproductive disorder. But a paper published in The Lancet argues the name is misleading. Reproductive physiologist Heidi Vanden Brink of Texas A&M is among those making the case for renaming it polyendocrine metabolic ovarian syndrome, or PMOS. The cruel irony of the current name, she notes, is that you do not need to have polycystic ovaries to have the condition at all.
What makes the disorder truly dangerous lies beyond the reproductive system. Insulin resistance, Type 2 diabetes, cardiovascular disease, and liver problems follow in its wake. So do anxiety, depression, and a measurable decline in quality of life — none of which the current name suggests. When a patient hears 'polycystic ovary syndrome,' she thinks of her ovaries. She does not think of her pancreas, her heart, or her mind.
Endocrinologist Melanie Cree of the University of Colorado highlighted the confusion this creates when treating teenagers. Adolescents with the condition are diagnosed through metabolic markers, not ovary ultrasounds — yet they are told they have an ovarian disease, then watch doctors focus entirely on blood sugar and hormones. The disconnect breeds mistrust. A better name would align the diagnosis with the actual treatment.
Vanden Brink argues the renaming is not merely semantic. It signals that PMOS demands a multidisciplinary team — not just a gynecologist, but an endocrinologist, a dietitian, a mental health professional. Reframing the condition as a metabolic and endocrine disorder could accelerate diagnosis, reduce stigma, and open doors to the research funding currently reserved for diseases like diabetes and heart disease. For the millions living with it, that shift in language represents something larger: recognition that their suffering spans the whole body, and that their care should too.
A condition that touches the lives of roughly 170 million adolescents and women worldwide is getting a new name—one that researchers say finally tells the truth about what it actually does to the body.
For decades, polycystic ovary syndrome, or PCOS, has been understood as a reproductive disorder. The name itself points squarely at the ovaries. But a paper published in The Lancet proposes calling it polyendocrine metabolic ovarian syndrome, or PMOS, to capture something the medical establishment has been slow to acknowledge: this condition is not primarily about the ovaries at all. It is a whole-body disease that disrupts metabolism, hormones, and mental health in ways the old name never suggested.
Heidi Vanden Brink, a reproductive physiologist at Texas A&M, helped make the case for the change. "For decades, we have been referring to a syndrome that doesn't fully represent the complexity of the condition," she said. The problem runs deep. One in eight women has PCOS globally. In Texas, the rate climbs to one in seven. Yet many go undiagnosed or are misdiagnosed because the symptoms—irregular periods, severe acne, male-pattern hair growth, infertility—get scattered across different specialists, and no one sees the full picture. The diagnosis itself requires at least two of three features: irregular menstrual cycles, elevated testosterone, and either polycystic ovaries or elevated Anti-Mullerian Hormone. But here is the cruel irony: you do not need to have polycystic ovaries to have the condition. The name is a lie.
What makes PMOS truly dangerous is what happens beyond the reproductive system. The condition carries a heavy metabolic load: insulin resistance, Type 2 diabetes, cardiovascular disease, and liver problems follow in its wake. It also damages mental health, contributing to anxiety, depression, and a measurable decline in quality of life. None of this appears in the name. When a patient hears "polycystic ovary syndrome," she thinks of her ovaries. She does not think of her pancreas, her heart, or her mind.
Melanie Cree, an endocrinologist at the University of Colorado and co-author of the Lancet paper, pointed out how confusing the old name becomes when treating teenagers. Adolescents already face metabolic stress from puberty alone. Add PCOS to that, and their insulin resistance spikes. But doctors do not diagnose PCOS in teens using ovary ultrasounds—they look for metabolic markers instead. So a girl and her parents hear she has a disease of the ovaries, then watch the doctor ignore the ovaries entirely and focus on blood sugar and hormone levels. The disconnect breeds confusion and mistrust. A better name would align the diagnosis with the actual treatment.
Vanden Brink emphasized that renaming the condition is not merely semantic. It signals that PMOS requires a multidisciplinary team: not just a gynecologist, but an endocrinologist, a dietitian, a mental health professional. The current name encourages siloed thinking. It keeps reproductive specialists in one lane and metabolic specialists in another, while patients fall through the gaps. Many go undiagnosed for years because their symptoms get dismissed or misunderstood, particularly in younger women whose complaints are often attributed to stress or weight.
A clearer name could accelerate diagnosis, improve coordination of care, and deliver better long-term outcomes. It could also shift the conversation away from fertility alone, reducing the stigma that surrounds the condition and opening doors to broader research funding. Right now, PMOS is often framed as a fertility problem—a woman's problem, a reproductive problem. Reframe it as a metabolic and endocrine disorder, and suddenly it becomes a disease that deserves the same research attention as diabetes or heart disease.
For the 170 million women living with this condition, the name change represents something larger: recognition that their suffering is not confined to one organ system, and that their care should reflect that reality.
Notable Quotes
For decades, we have been referring to a syndrome that doesn't fully represent the complexity of the condition. PMOS is about more than ovaries.— Heidi Vanden Brink, reproductive physiologist, Texas A&M
The new name better aligns with more of what patients may struggle with and helps explain why we often recommend therapies to treat metabolic conditions.— Melanie Cree, endocrinologist, University of Colorado
The Hearth Conversation Another angle on the story
Why does the name matter so much? It's still the same disease either way.
The name shapes how doctors think about it and how patients understand themselves. If you call something a reproductive disorder, gynecologists treat it in isolation. Endocrinologists never get involved. The patient thinks her problem is about having babies, not about her heart or her blood sugar.
But the condition does affect fertility. That's real.
Absolutely. But it also affects insulin, cardiovascular health, mental health. The old name made those invisible. A teenager gets told she has a disease of the ovaries, then her doctor ignores the ovaries and checks her glucose levels. That contradiction breeds confusion.
So this is about getting the right specialists involved?
Partly. But it's also about how patients see themselves. If you're told you have a metabolic disorder, you understand why diet and exercise matter. You understand why you need an endocrinologist. The old name made those things seem optional or secondary.
What about the women who are already diagnosed? Does the name change help them?
It helps them understand why their care is fragmented, why they need multiple doctors, why their mental health struggles are connected to their physical symptoms. And it helps them advocate for themselves—they can say, 'This is a metabolic condition,' not just 'I have ovary problems.'
And the ones who haven't been diagnosed yet?
That's where it matters most. A clearer name means doctors recognize it faster. Fewer women go years without answers. Earlier diagnosis means earlier intervention, which changes the trajectory of the disease.